Livzon Pharmaceutical Group Inc. Issues Supplemental Announcement on Revised Proxy Form

Key Highlights:

• Livzon Pharmaceutical Group Inc. has issued a supplemental announcement regarding the proxy form for its upcoming 2025 Annual General Meeting (AGM) to be held on 29 May 2026.
• The previously issued proxy form (the “Original Proxy Form”) has been rendered void and replaced by a Revised Proxy Form.
• The only changes made are typographical and formatting adjustments; there are no substantive changes to the content or resolutions contained within the proxy form.
• Shareholders who have already submitted the Original Proxy Form are required to complete and submit the Revised Proxy Form.
• The methods of submission, deadlines, and other requirements for the proxy form remain unchanged.

Details of the Announcement

Livzon Pharmaceutical Group Inc. (“the Company”) has announced the publication of a Revised Proxy Form for its forthcoming 2025 AGM. This decision was necessitated solely by the need to correct typographical and formatting issues identified in the Original Proxy Form issued on 23 April 2026. The Company has emphasized that no substantive or material changes have been made to the resolutions or any content within the proxy form.

The Revised Proxy Form has been made available for shareholders on both the website of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) as well as the Company’s official website (www.livzon.com.cn).

Important Information for Shareholders

• All shareholders are required to use the newly issued Revised Proxy Form for submission of their voting instructions for the upcoming AGM. The Original Proxy Form is now void and will not be accepted.
• Shareholders who had previously completed and submitted the Original Proxy Form must re-complete and re-submit using the Revised Proxy Form.
• Submission methods, deadlines, and associated requirements remain unchanged. Shareholders should carefully refer to the notes in the Revised Proxy Form for procedural details.

Potential Impact on Share Value

The announcement is administrative in nature and relates solely to typographical and formatting corrections in the proxy form. There are no changes to the actual content or resolutions for the AGM. As such, there is no new or material information disclosed that would be expected to influence the share price of Livzon Pharmaceutical Group Inc. This announcement is unlikely to be price sensitive.

Board Composition

As of the date of the announcement, the Board of Directors of Livzon Pharmaceutical Group Inc. is comprised as follows:

• Executive Director: Mr. Tang Yanggang (Vice Chairman)
• Non-Executive Directors: Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi, Mr. Qiu Qingfeng
• Employee Representative Director: Ms. Ran Yongmei
• Independent Non-Executive Directors: Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao

The Company has apologized for any inconvenience caused by the formatting adjustments and expressed appreciation for shareholders’ understanding and support.

Disclaimer: This article is a detailed summary based on the official supplemental announcement issued by Livzon Pharmaceutical Group Inc. on 24 April 2026. It is intended for informational purposes only and does not constitute investment advice. Investors should refer to the original documents and consult their financial advisors before making any investment decisions.

View LIVZON PHARMA Historical chart here